AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20938439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) (1.2 g per day) for 12 weeks
Number of subjects: 417
Study 20938439 — intervention group
Group type: COMPARATOR
Intervention: High-SFA diet
Number of subjects: 417
Study 20938439 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fatty acids diet
Number of subjects: 417
Study 20938439 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate (LFHCC) diet supplemented with placebo
Number of subjects: 417
Study 19994586 — intervention group
Group type: EXPERIMENTAL
Intervention: Superfine dispersed beta-1,3-glucan
Number of subjects: 0
Study 19994586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17224858 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg/day initially, increased to 20 mg/day after 1 week)
Number of subjects: 100
Study 17224858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17224858 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram + HT (10 mg/day initially, increased to 20 mg/day after 1 week)
Number of subjects: 100
Study 17224858 — intervention group
Group type: COMPARATOR
Intervention: Placebo + HT
Number of subjects: 100
Study 17224858 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 100
Study 17224858 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram + HT
Number of subjects: 100
Study 16595221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg of desogestrel plus 0.030 mg of ethinyl E2 daily for 12 months
Number of subjects: 36
Study 16595221 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of cyproterone acetate plus 0.035 mg of ethinyl E2 daily for 12 months
Number of subjects: 36
Study 12883329 — intervention group
Group type: COMPARATOR
Intervention: Oxygen administration for 1 hour
Number of subjects: 0
Study 12883329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11023928 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/d for 3 days and then 500 mg/wk for 3 months
Number of subjects: 302
Study 11023928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 9273524 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of intravenous opiate injections and administration of methadone
Number of subjects: 43
Study 9273524 — intervention group
Group type: COMPARATOR
Intervention: Continued injecting drug use (Control group)
Number of subjects: 43
Study 1642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural clonidine 25 micrograms h‐1
Number of subjects: 0
Study 1642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural clonidine 50 micrograms h‐1
Number of subjects: 0
Study 1642909 — intervention group
Group type: COMPARATOR
Intervention: Low dose extradural morphine
Number of subjects: 0
Study 1642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine and clonidine
Number of subjects: 0
Study 1642909 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural clonidine groups
Number of subjects: 0
Study 1642909 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 6518665 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyldopa (A)
Number of subjects: 95
Study 6518665 — intervention group
Group type: COMPARATOR
Intervention: clonidine hydrochloride (C)
Number of subjects: 95
Study 6518665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and A)
Number of subjects: 95
Study 30795978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary authored by a close relative
Number of subjects: 75
Study 30795978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diary)
Number of subjects: 75
Study 30169407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 50
Study 30169407 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex 4 mg/kg
Number of subjects: 50
Study 30169407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg and Sugammadex 4 mg/kg
Number of subjects: 50
Study 28370208 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthorexia nervosa (ON)
Number of subjects: 505
Study 28370208 — intervention group
Group type: COMPARATOR
Intervention: Anorexia nervosa (AN)
Number of subjects: 505
Study 28370208 — intervention group
Group type: COMPARATOR
Intervention: Bulimia nervosa (BN)
Number of subjects: 505
Study 28370208 — intervention group
Group type: COMPARATOR
Intervention: Binge-eating disorder (BED)
Number of subjects: 505
Study 25424049 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% benzocaine
Number of subjects: 20
Study 25424049 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 20
Study 23150144 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg on 2 consecutive days each month (2CDM)
Number of subjects: 1229
Study 23150144 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg daily
Number of subjects: 1229
Study 23150144 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 75 mg 2CDM
Number of subjects: 1229
Study 21496415 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) at a daily dose of 20 mg
Number of subjects: 96
Study 21496415 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a mean dose of 11.7±2.6 mg/week
Number of subjects: 96
Study 18510807 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800 mg/day)
Number of subjects: 49
Study 18510807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/day)
Number of subjects: 49
Study 18510807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DHA and lutein
Number of subjects: 49
Study 18510807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 17130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment during the DCCT
Number of subjects: 1205
Study 17130504 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment during the DCCT
Number of subjects: 1205
Study 17130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cohorts (intensive and conventional)
Number of subjects: 1205
Study 17130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior intensive diabetes treatment
Number of subjects: 1205
Study 17130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disease risk factors (waist-to-hip ratio, smoking, hypertension, hypercholesterolemia)
Number of subjects: 1205
Study 17130504 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean HbA(1c) levels before enrollment, during the DCCT, and during the EDIC study
Number of subjects: 1205
Study 15510240 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0
Study 11516093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (glycosylated recombinant human G‐CSF) 5 microg per kg body weight subcutaneously daily from day 8 after starting chemotherapy.
Number of subjects: 112
Study 11516093 — intervention group
Group type: COMPARATOR
Intervention: No cytokine
Number of subjects: 112
Study 9024018 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed anesthetic risk information
Number of subjects: 334
Study 9024018 — intervention group
Group type: COMPARATOR
Intervention: Routine anesthetic risk information (control)
Number of subjects: 334
Study 8381931 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (40 mU.m‐2.min‐1)
Number of subjects: 7
Study 8381931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8381931 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (converting enzyme inhibitor)
Number of subjects: 7
Study 3472510 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheters
Number of subjects: 60
Study 3472510 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheters
Number of subjects: 60
Study 28949012 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg once daily (OD) PF-04965842
Number of subjects: 59
Study 28949012 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg OD PF-04965842
Number of subjects: 59
Study 28949012 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg twice daily (TD) PF-04965842
Number of subjects: 59
Study 28949012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 27573560 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4/XELOX for 3 months (arm 3 m)
Number of subjects: 3759
Study 27573560 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4/XELOX for 6 months (arm 6 m)
Number of subjects: 3759
Study 24129358 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Number of subjects: 37
Study 24129358 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 37
Study 23878319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced T cells targeting ≥3 gag peptides
Number of subjects: 0
Study 23878319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced T cells
Number of subjects: 0
Study 23878319 — intervention group
Group type: COMPARATOR
Intervention: HLA-B*27, -B*57 and -B*58:01 alleles
Number of subjects: 0
Study 20034487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1 g/day) for 3 months
Number of subjects: 83
Study 20034487 — intervention group
Group type: COMPARATOR
Intervention: Control group (without fish oil)
Number of subjects: 83
Study 18937610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime-sulbactam
Number of subjects: 102
Study 18937610 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 102
Study 16737416 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg/day for 2 weeks
Number of subjects: 51
Study 14757967 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg sodium selenite (Se-Se)
Number of subjects: 47
Study 14757967 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped taking selenium (Se-0)
Number of subjects: 47
Study 14757967 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 200 microg sodium selenite (Plac-Se)
Number of subjects: 47
Study 14757967 — intervention group
Group type: COMPARATOR
Intervention: Placebo without selenium substitution (Plac-0)
Number of subjects: 47
Study 10830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence
Number of subjects: 2437
Study 10830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment and incidence density measures
Number of subjects: 2437
Study 10830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude DFS values
Number of subjects: 2437
Study 10830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted DFS
Number of subjects: 2437
Study 10830647 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of caries initiation and progression
Number of subjects: 2437
Study 11990103 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest harness
Number of subjects: 6
Study 11990103 — intervention group
Group type: COMPARATOR
Intervention: Sit harness
Number of subjects: 6
Study 1626175 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler velocimetry with an index above 0.54 for induction of childbirth in 52 pregnancies
Number of subjects: 187
Study 1626175 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring methods in 132 cases
Number of subjects: 187
Study 1626175 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of fetuses beyond term by umbilical artery velocimetry
Number of subjects: 187
Study 6373156 — intervention group
Group type: COMPARATOR
Intervention: Glaucine syrup 30 mg 3-times daily for 7 days
Number of subjects: 130
Study 6373156 — intervention group
Group type: COMPARATOR
Intervention: Codeine syrup 30 mg 3-times daily for 7 days
Number of subjects: 130
Study 6373156 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucine capsules 30 mg 3-times daily for 28 days
Number of subjects: 130
Study 31281005 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based exercise programme (aerobic and resistance exercise for a minimum of 25min per day, three times a week for 10 weeks)
Number of subjects: 52
Study 31281005 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 52
Study 29753693 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) 600 mg and sodium ferrous citrate (SFC) 942 mg
Number of subjects: 0
Study 29753693 — intervention group
Group type: COMPARATOR
Intervention: 5-aminolevulinic acid (ALA) alone
Number of subjects: 0
Study 29753693 — intervention group
Group type: COMPARATOR
Intervention: Sodium ferrous citrate (SFC) alone
Number of subjects: 0
Study 29753693 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA+SFC
Number of subjects: 0
Study 27694586 — intervention group
Group type: EXPERIMENTAL
Intervention: Refobacin bone cement R
Number of subjects: 62
Study 27694586 — intervention group
Group type: COMPARATOR
Intervention: Palacos R + G
Number of subjects: 62
Study 24710342 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids treatment within 24 hours after admission
Number of subjects: 106
Study 22305244 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT+PR (Group 2)
Number of subjects: 20
Study 22305244 — intervention group
Group type: COMPARATOR
Intervention: PR (Group 1)
Number of subjects: 20
Study 20105415 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 121
Study 20105415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 18725648 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 252
Study 18725648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐Adenosylmethionine (SAMe)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CP)
Number of subjects: 0
Study 15953803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 12881343 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Tenon's capsule resection with adjunctive mitomycin C (MMC)
Number of subjects: 92
Study 12881343 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma valve implant without PTCR (control group)
Number of subjects: 92
Study 12881343 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PTCR with MMC and control)
Number of subjects: 92
Study 10966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab treatment during coronary artery bypass grafting
Number of subjects: 0
Study 10966009 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of EPILOG and EPISTENT studies
Number of subjects: 0
Study 8937234 — intervention group
Group type: EXPERIMENTAL
Intervention: Small balloon catheter
Number of subjects: 46
Study 8937234 — intervention group
Group type: COMPARATOR
Intervention: Normal balloon (Robinson's catheter with two condoms)
Number of subjects: 46
Study 1567745 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution (S-I)
Number of subjects: 124
Study 1567745 — intervention group
Group type: COMPARATOR
Intervention: Golytely solution (S-II)
Number of subjects: 124
Study 1567745 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive irrigation with antibiotics
Number of subjects: 124
Study 1567745 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin and neomycin base
Number of subjects: 124
Study 2865218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol 1 mg (BP1)
Number of subjects: 100
Study 2865218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol 2 mg (BP2)
Number of subjects: 100
Study 2865218 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2.5 mg (LR)
Number of subjects: 100
Study 2865218 — intervention group
Group type: COMPARATOR
Intervention: Butalbital 75 mg (BT)
Number of subjects: 100
Study 2865218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100
Study 2865218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (BP1 and BP2)
Number of subjects: 100
Study 2865218 — intervention group
Group type: COMPARATOR
Intervention: Butalbital (BT)
Number of subjects: 100
Study 2865218 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (LR)
Number of subjects: 100
Study 31623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility intervention
Number of subjects: 40
Study 31623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength intervention
Number of subjects: 40
Study 30352399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 202
Study 30352399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 28033302 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance training (IRT) at 30% of maximum voluntary contraction
Number of subjects: 40
Study 28033302 — intervention group
Group type: COMPARATOR
Intervention: Isometric resistance training (IRT) at 5% of maximum voluntary contraction
Number of subjects: 40
Study 24885942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate 3000 mg/day
Number of subjects: 35
Study 24885942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22273665 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe PVD
Number of subjects: 0
Study 22273665 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PVD severity
Number of subjects: 0
Study 20176715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy
Number of subjects: 62
Study 20176715 — intervention group
Group type: COMPARATOR
Intervention: Baseline RV peak systolic strain
Number of subjects: 62
Study 20176715 — intervention group
Group type: EXPERIMENTAL
Intervention: RV peak systolic strain at 48 to 72 hours
Number of subjects: 62
Study 19319752 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinergy wheelchair wheels
Number of subjects: 13
Study 19319752 — intervention group
Group type: COMPARATOR
Intervention: Conventional steel-spoked wheelchair wheels
Number of subjects: 13
Study 15857067 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride-iontophoresis (NaF)
Number of subjects: 50
Study 15857067 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution of hydroxy-ethyl-methacrylate and glutaraldehyde (HEMA-G)
Number of subjects: 50
Study 15857067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents (NaF and HEMA-G)
Number of subjects: 50
Study 15857067 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth requiring repeat dosage
Number of subjects: 50
Study 12769403 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Number of subjects: 0
Study 12769403 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 0
Study 12091047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 12091047 — intervention group
Group type: COMPARATOR
Intervention: Control (no thrombolytic therapy)
Number of subjects: 0
Study 9874451 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP (etoposide 120 mg/m2, epirubicin 30 mg/m2, cisplatin 40 mg/m2 on Days 1 and 8)
Number of subjects: 131
Study 9874451 — intervention group
Group type: COMPARATOR
Intervention: FEP (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cisplatin 80 mg/m2 on Day 1)
Number of subjects: 131
Study 9874451 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP
Number of subjects: 131
Study 9874451 — intervention group
Group type: COMPARATOR
Intervention: FEP
Number of subjects: 131
Study 8594118 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerant topical anesthetic
Number of subjects: 90
Study 8594118 — intervention group
Group type: COMPARATOR
Intervention: Placebo topical spray
Number of subjects: 90
Study 8594118 — intervention group
Group type: COMPARATOR
Intervention: No-spray control
Number of subjects: 90
Study 2087335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ga-As laser applied to acupuncture points (LI 10, 11, 12, Lu 5, SJ 5)
Number of subjects: 49
Study 2087335 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 38680 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg atropine
Number of subjects: 0
Study 38680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg hyoscine
Number of subjects: 0
Study 38680 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrronium
Number of subjects: 0
Study 38680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticholinergic premedication)
Number of subjects: 0
Study 6553250 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tubing changed every 24 hours
Number of subjects: 130
Study 6553250 — intervention group
Group type: COMPARATOR
Intervention: IV tubing changed every 48 hours
Number of subjects: 130
Study 6553250 — intervention group
Group type: COMPARATOR
Intervention: IV tubing changed every 72 hours
Number of subjects: 130
Study 29580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) implementation program
Number of subjects: 0
Study 27459428 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based tobacco education program
Number of subjects: 134
Study 27459428 — intervention group
Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 134
Study 23794465 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg·kg(‐1) daily for up to 10 days)
Number of subjects: 217
Study 23794465 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study 22430522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous traction
Number of subjects: 65
Study 22430522 — intervention group
Group type: COMPARATOR
Intervention: Skeletal traction
Number of subjects: 65